These neoplasms vary from indolent to highly aggressive tumors, so their management is informed by the primary site, functionality of the tumor, extent of the metastatic disease, proliferation rate (Ki-67), and the clinical presentation of the patient. Here, MKI67 is linked to neoplasm.